Empagliflozin: Therapeutic area: Kidney disease, nephrology: Reimbursement Review
Abstract
What is chronic kidney disease?: • Chronic kidney disease (CKD) is a heterogeneous group of disorders that can progress to end-stage kidney disease (ESKD) and result in poor health-related quality of life (HRQoL), high morbidity, and premature mortality. • From 2010 to 2015, the prevalence of CKD was 71.9 per 1,000 people in Canada. In 2021, more than 6,000 people received kidney replacement therapy (dialysis or pre-emptive kidney transplant) in Canada.
What are the treatment goals and current treatment options for ckd?: • Core outcomes identified by patients, caregivers, and health professionals were mortality, kidney function, life participation, and cardiovascular disease. Clinicians advocate for patients with CKD to have access to treatments that halt or delay disease progression, prevent kidney failure, reduce mortality, and improve HRQoL, while minimizing side effects. • Dapagliflozin and canagliflozin were considered relevant treatments to compare with empagliflozin.
What is empagliflozin and why did canada’s drug agency conduct this review?: • Empagliflozin is a drug that is available as an oral tablet. Health Canada has approved empagliflozin to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, ESKD, and cardiovascular and renal death in adults with CKD. • At the request of the participating public drug programs, Canada’s Drug Agency (CDA-AMC) reviewed empagliflozin to inform a recommendation on whether it should be reimbursed for CKD…
Read the paper
Related studies
- Risk Factors for Coronavirus Disease 2019 (COVID-19) Death in a Population Cohort Study from the Western Cape Province, South Africa
- Global and regional estimates of genital human papillomavirus prevalence among men: a systematic review and meta-analysis
- A methodology for assessing deployment trauma and its consequences in OEF/OIF/OND veterans: The TRACTS longitudinal prospective cohort study
- Post‑COVID‑19 Syndrome in Outpatients: a Cohort Study
- Factors Influencing Primary and Secondary Implant Stability—A Retrospective Cohort Study with 582 Implants in 272 Patients
- Electroacupuncture for Painful Diabetic Peripheral Neuropathy: A Multicenter, Randomized, Assessor-Blinded, Controlled Trial
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.